Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
Clinical trial NCT02455011 · COMPLETED
Trial details
- NCT number
- NCT02455011
- Sponsor
- REMD Biotherapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-01
- Primary completion
- 2018-01-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.